Nanobiotix expands operations into the US

Senior pharmaceutical executive appointed as Vice President of Corporate Development

Nanobiotix, a French clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, has opened its first US office in Boston, MA.

The company says this is an important step for its international development strategy and will provide it with access to knowhow and a high level of expertise in research into nanomedicine.

To lead the development of the US affiliate, Patrick Tricoli has been appointed as Vice President of Corporate Development. He has more than 25 years’ experience in the pharmaceutical industry and joins the company from Sanofi, where he held a number of positions in both Corporate and Research and Development. In recent years he has focused on international business development and partnering activities.

Nanobiotix is an oncology focused nanomedicine company developing an innovative nanoparticle technology. The company is developing new tools for cancer which utilise a physical mode of action at the cellular level of the cancer cell. This disruptive approach may reshape future treatment opportunities.

The company's NanoXray technology comprises three products having potential in cancer therapy. They selectively increase the efficacy of radiotherapy in the tumour cell.